HealthEquity (FRA:2HE) Research & Development: €230 Mil (TTM As of Apr. 2026)


FRA:2HE HealthEquity Inc FRA:2HE
92 GF Score
Price €72.00
GF Value €83.82
! 1 Warning Sign
View Full Analysis

What is HealthEquity Research & Development?

HealthEquity FRA:2HE -4.00% 92 Research & Development is €230 Mil as of Apr. 2026. GuruFocus rates FRA:2HE with a GF Score™ of 92/100 and a GF Value™ of €83.82. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. HealthEquity's Research & Development for the three months ended in Apr. 2026 was €58 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Apr. 2026 was €230 Mil.

HealthEquity  (FRA:2HE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

HealthEquity Research & Development Related Terms

HealthEquity Research & Development Historical Data

* Premium members only.

The historical data trend for HealthEquity's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HealthEquity Research & Development Chart

HealthEquity Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 139.11 179.45 200.87 231.37 223.40

HealthEquity Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.68 55.54 56.62 59.87 57.94
FRA:2HE
92GF Score
HealthEquity Inc FRA:2HE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HealthEquity Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €230 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €230 Mil mean?
HealthEquity (FRA:2HE) has a Research & Development of €230 Mil as of Apr. 2026. Research and development expense is the total cost for research and development activities. View historical data on HealthEquity and its competitors.
Is HealthEquity's Research & Development too high?
HealthEquity's current Research & Development is €230 Mil. Overall, HealthEquity has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does HealthEquity's Research & Development compare to HNGE and TEM?
HealthEquity's Research & Development of €230 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on HealthEquity and its competitors. HealthEquity's current Research & Development is €230 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthEquity stock overvalued right now?
HealthEquity (FRA:2HE) has a current Research & Development of €230 Mil. The stock's GF Value™ is €83.82, compared to a current price of €72.00 — trading 14.1% below its estimated fair value. The current Research & Development is €230 Mil. HealthEquity's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For HealthEquity (FRA:2HE), the current Research & Development is €230 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HealthEquity (FRA:2HE) Overvalued in 2026?

Based on GuruFocus' analysis, HealthEquity stock appears to be undervalued. The current stock price of €72.00 is trading 14.1% below its estimated GF Value™ of €83.82.

Key valuation signals for FRA:2HE:

  • Research & Development: €230 Mil
  • GF Value™: €83.82 vs. price of €72.00 (14.1% below fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the FRA:2HE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HealthEquity Business Description

Other Exchanges HQY:USA
Address 15 West Scenic Pointe Drive, Suite 100, Draper, UT, USA, 84020
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
92GF Score

Get the complete analysis for FRA:2HE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€72.00
Price
€83.82
GF Value